HLA-E was upregulated in residual AML versus ND AML, suggesting potential differences in microenvironment favoring immune resistance in AML cases more recalcitrant to up-front therapy (p=<0.00001) (Figure 2B). This evidence concerns the gene HLA-E and acute myeloid leukemia.